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Background: In February 1999, the National Cancer Institute (NCI) issued a clinical alert
based on five randomized trials that reported better overall survival (OS) with concurrent
chemoradiotherapy (CCRT) than with surgery or radiation alone for locoregional cervical
cancer.This study analyzes data from the surveillance epidemiology and end results (SEER)
program to evaluate the improvement in survival in the era of CCRT.
Methods: The SEER database was queried for FIGO stages IB2–IVA cervical cancer
patients treated with radiotherapy between 1995 and 2002. Patients diagnosed between
1999 and 2002 (CCRT era) were assumed to have received CCRT more frequently than
patients diagnosed between 1995 and 1998 (RT era). Cases were stratified by period of
diagnosis, age, and SEER region. OS and cause specific survival (CSS) were compared
between the two time periods with chi-square log-rank tests. Multivariable Cox models
were also used to compare OS and CSS between the two time periods, with adjustment
for stratification variables and other covariates.
Results: The study included 3517 patients. Unadjusted OS and CSS were significantly
improved in 1999–2002 compared with 1995–1998 (OS: p<0.001, hazard ratio (HR): 0.81;
CSS: p<0.001, HR: 0.79). Significant improvements in OS and CSS were retained after
adjustment for multiple variables (multivariable OS HR 0.78; CSS HR 0.76).
Conclusion: Cervical cancer patients treated with radiotherapy after 1999 had improved
OS and CSS compared with patients treated before 1999, likely reflecting increased usage
of CCRT.This study adds to the population-level evidence supporting the adoption of CCRT
as the standard of care for locoregional cervical cancer.
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INTRODUCTION
Prior to 1999, patients with cervical cancer were treated primarily
with surgery or definitive radiation therapy. In February 1999,
the National Cancer Institute (NCI) issued a clinical alert (1)
based on five randomized clinical trials in locoregional cervical
cancer that reported improved overall survival (OS) with concur-
rent chemoradiotherapy (CCRT) when compared with surgery or
radiation alone (2–6). This resulted in the rapid adoption of CCRT
for definitive treatment or selective adjuvant treatment for local-
ized cervical cancer. In contrast, a clinical trial conducted by the
NCI of Canada did not show a survival advantage with CCRT (7).
However, three meta-analyses, including one from Canadian inves-
tigators, demonstrated improved OS and progression-free survival
with CCRT (8–10).
This study seeks to confirm whether OS improved significantly
in the United States after the NCI alert was issued (CCRT era).
Our hypothesis is that the adoption of CCRT for locoregional
cervical cancer in the United States was rapid after the NCI alert
and resulted in an observable increase in OS. While chemotherapy
usage was not recorded in the SEER*Stat analytical interface for
the surveillance epidemiology and end results (SEER) database,
we considered any rapid and significant change in survival rates
around the time of the NCI alert to be indirect evidence of changes
in chemotherapy usage because no other known changes occurred
for the cervical cancer patient population during the study time
period.
MATERIALS AND METHODS
DATA SOURCE
The SEER database is a NCI program that currently includes
18 regions. Since the data for Greater California (excluding San
Francisco, Los Angeles, and San Jose), Kentucky, Louisiana, New
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Jersey, and Greater Georgia (excluding Atlanta and Rural Geor-
gia) were not available for years prior to 2000, we excluded data
from these four regions in our analyses. Therefore, 13 regions
were included in our analyses. Compared to the general US popu-
lation, the SEER population is similar with respect to poverty and
education, but is somewhat more urban and has a higher propor-
tion of foreign-born persons (11). SEER data (2011 submission)
included cancer cases diagnosed up to and including year 2009,
with a follow-up cutoff date of December 31, 2009. Chemother-
apy usage was not recorded in the SEER*Stat analytical interface
for the SEER database; so, it could not be incorporated explicitly
into our analysis.
PATIENT SELECTION
SEER data were queried using SEER*Stat version 7.1.0 software
(12). Patients were selected from the 13 regions that were included
in both time periods using the following inclusion criteria: malig-
nancy of the cervix uteri, FIGO stages IB2–IVA, diagnosis years
1995–2002, radiotherapy given, and no other malignancy. FIGO
stages IB2–IVA were chosen to correspond with the patient popu-
lations allowed onto the randomized clinical trials. Stages II–IVA
were recoded from the SEER Extent of Disease variable “EOD
10 – extent (1988–2003).” Stage IB2 included the subset of stage I
patients with tumor size >4 cm. Only patients with cervical cancer
as their sole malignancy were included to allow analysis of both OS
and cause specific survival (CSS) (using the “SEER cause-specific
death classification” variable) in the same cohort.
SELECTION OF TIME PERIODS
Since the CCRT recommendation was made in 1999, we selected
patients diagnosed in the four prior years (1995–1998) and the
four subsequent years (1999–2002) for comparison. Patients diag-
nosed between 1995 and 1998 were presumed to have received
radiotherapy and less frequently chemotherapy, while those diag-
nosed between 1999 and 2002 were presumed to have received
CCRT more frequently.
STATISTICAL METHODS
Cases were stratified by period of diagnosis (1995–1998 and 1999–
2002), age group, and SEER regions. Log-rank tests were used
to test the heterogeneity within each of the two time periods.
Chi-square tests were used to compare the distributions of the
diagnostic characteristics between the two time periods. Log-rank
tests were used to compare OS and CSS in 1999–2002 and 1995–
1998 without adjustment for any other variables. Competing risk
methods (“cmprsk” package, R software, Version 2.14) were used
to compare CSS for 1995–1998 and 1999–2002, with other causes
of death considered as competing risks to cervical cancer death.
In addition, OS and CSS by the time periods were compared with
log-rank tests stratified by age group and by SEER region. Multi-
variable Cox regression models were used to obtain hazard ratios
(HRs) for OS and CSS for the time period comparison,with adjust-
ment for age, region, and other covariates individually and jointly.
Stepwise variable selection procedures were used to obtain the final
models. SAS version 9.3 was used for all analyses. R version 2.13.1
was used to plot Kaplan–Meier survival curves.
RESULTS
The study included a total of 3517 patients from the 13 regions
in the SEER database that had data spanning the entire study
period. There were 1758 patients (50%) in 1995–1998 and 1759
patients (50%) in 1999–2002. Patients diagnosed in 1995–1998
had longer survival follow up (approximately 0–170 months) than
those diagnosed in 1999–2002 (approximately 0–120 months) at
the follow-up cutoff date of December 31, 2009.
The Kaplan–Meier OS curves (Figure 1) for each of the 8 years
comprising the two time periods demonstrate a difference in OS
between the two time periods (1995–1998 versus 1999–2002) but
similarity in OS among the years within each time period. There
is no significant heterogeneity within each of the two time periods
(OS: 1995–1998 p= 0.69, 1999–2002 p= 0.88; CSS: 1995–1998
p= 0.69, 1999–2002 p= 0.68).
Table 1 summarizes the distributions of patient, tumor, and
treatment characteristics by the 4-year time periods (1995–1998
and 1999–2002). Note that small size subgroups were com-
bined for statistical analyses (Table S1 in Supplementary material
includes the original variable subgroups). We excluded “Tumor
Size” because of the large proportion of unknown size cases. The
results indicate that, with the exception of lymph node status
and radiation type (p≤ 0.05), there were no significant differ-
ences between the two time periods for patient, tumor, or treat-
ment characteristics. The percentage of all patients who received
“hysterectomy/exenteration/other surgery” was 28.8% (30.6% for
1995–1998, 27.1% for 1999–2002). Unadjusted analyses demon-
strated that OS was significantly improved in 1999–2002 compared
with 1995–1998 (p< 0.001; HR 0.81 with 95% CI: 0.74–0.88).
The median OS time increased from 37 months (95% CI: 34–
42 months) in 1995–1998 to 64 months (95% CI: 54–84 months)
in 1999–2002 (Figure 2). We also found that CSS was significantly
improved (p< 0.001; HR 0.79; 95% CI: 0.71–0.86). The median
FIGURE 1 | Kaplan-Meier overall survival curves for individual years
1995–2002.
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Table 1 | Patient, tumor, and treatment characteristics by 4-year of diagnosis groups (N = 3517).
Variable Year 1995–1998 Year 1999–2002 Total p-Value
# Patients (%) # Patients (%)
N 1758 1759 3517
Age group 0.81
<41 372 (21.1) 360 (20.5) 732 (20.8)
41–55 698 (39.7) 715 (40.7) 1413 (40.2)
>55 688 (39.1) 684 (38.9) 1372 (39.0)
Race 0.55
White 1239 (70.5) 1256 (71.4) 2495 (70.9)
Non-white 519 (29.5) 503 (28.6) 1022 (29.1)
Marital status 0.23
Married 747 (42.5) 712 (40.5) 1459 (41.5)
Unmarried 1011 (57.5) 1047 (59.5) 2058 (58.5)
FIGO stage 0.75
IB2 221 (12.6) 225 (12.8) 446 (12.7)
II 877 (49.9) 855 (48.6) 1732 (49.3)
III + IVA 660 (37.5) 679 (38.6) 1339 (38.0)
Histology 0.59
Squamous cell carcinoma 1402 (79.7) 1383 (78.6) 2785 (79.2)
Adenocarcinoma 168 (9.6) 186 (10.6) 354 (10.0)
Other/unknown 188 (10.7) 190 (10.8) 378 (10.8)
Lymph node status 0.006
Distant LN+ 140 (7.96) 131 (7.45) 271 (7.71)
LN− 872 (49.6) 945 (53.7) 1817 (51.7)
Regional LN+ 253 (14.4) 276 (15.7) 529 (15.0)
Other/unknown 493 (28.0) 407 (23.1) 900 (25.6)
Surgery extent 0.072
No surgery/incisional biopsy/unknown 1101 (62.6) 1153 (65.6) 2254 (64.1)
Local ablation or excision 119 (6.8) 129 (7.3) 248 (7.1)
Hysterectomy/exenteration/other surgery 538 (30.6) 477 (27.1) 1015 (28.8)
Radiation type 0.026
Combined EBRT+brachytherapy 1089 (62.0) 1025 (58.3) 2114 (60.1)
EBRT/brachytherapy/other 669 (38.0) 734 (41.7) 1403 (39.9)
Red color used to highlight statistically significant p-values.
CSS increased from 52 months (95% CI: 44–71 months) in 1995–
1998 to over 98 months (lower bound of the 95% CI, median not
reached) in 1999–2002 (Figure 3). The percentage of non-cause
specific death was 18% in 1995–1998 and was 17.5% in 1999–
2002. Statistical methods that consider other causes of death as
competing risks to cervical cancer deaths confirmed a significant
difference in CSS between the two time periods (p< 0.0001) (data
not shown).
When stratified by age group, OS and CSS survival were sig-
nificantly improved when comparing 1995–1998 with 1999–2002
in all age groups (Table 2). The HR (OS and CSS) of 1999–2002
compared to 1995–1998 was ≤0.85 in all age groups.
Table 3 shows the comparison of OS and CSS between 1995–
1998 and 1999–2002 stratified by SEER regions. With the exception
of Connecticut, Hawaii, and New Mexico, the HR of 1999–2002 to
1995–1998 in most regions (9/13 regions; 70%) was≤0.92. In par-
ticular, in San Francisco–Oakland SMSA, Metropolitan Detroit,
and Metropolitan Atlanta, the HRs for 1999–2002 relative to 1995–
1998 were ≤0.73. In contrast, Connecticut, Hawaii, and New
Mexico had HRs >1.00 (not statistically significant).
Cox regression models were used in order to examine changes
in survival between 1995–1998 and 1999–2002, adjusted by other
variables reported in the SEER database: race, marital status, FIGO
stage, histology, lymph node status, surgery extent, and radiation
type. Significant improvements in OS and CSS were observed after
adjustment for all of the characteristics individually (Table 4). The
HR for 1999–2002 compared to 1995–1998 was consistently 0.80
(95% CI: 0.74–0.88) for OS and 0.78 (95% CI: 0.71–0.86) for CSS
when adjusted for each of these variables individually.
We estimated the HR for levels of these characteristics, adjusted
for time period, as shown in Table 4. For example, when adjusted
by time period, the HR for OS for unmarried cases compared
to married cases was 1.25 (95% CI: 1.15–1.37). Similarly, the OS
HR was 1.43 (95% CI: 1.22–1.68) for FIGO stage II compared to
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FIGURE 2 | Unadjusted Kaplan–Meier overall survival curves by 4-year
time period (1999–2002 versus 1995–1998). Log-rank test p value and
hazard ratio (HR) for death are shown.
FIGURE 3 | Unadjusted Kaplan–Meier cause specific survival curves by
4-year time period (1999–2002 versus 1995–1998). Log-rank test p value
and hazard ratio (HR) for death are shown.
IB2, and it was 3.15 (95% CI: 2.68–3.70) for FIGO stage III+ IVA
compared to IB2.
Multivariable Cox regression models were used to compare the
OS and CSS between 1995–1998 and 1999–2002, adjusted simul-
taneously for all characteristics (Table 5: OS, Table 6: CSS). OS
and CSS were significantly improved in 1999–2002 compared to
1995–1998 when adjusted for all factors. The HR for death in 1999–
2002 compared to 1995–1998 was 0.78 for OS (95% CI: 0.71–0.85)
and was 0.76 for CSS (95% CI: 0.69–0.84). Significance levels and
HRs for categories within each variable are tabulated in Table 5
(OS) and Table 6 (CSS).
A simulation study was conducted to test the robustness of
these results under different assumptions for the proportions
of patients receiving CCRT in the two time periods. For exam-
ple, if we assumed that CCRT was given to 30% of the patients
diagnosed in 1995–1998 and 70% of the patients diagnosed in
1999–2002, the simulation suggested that 52% of the time the
log-rank tests for OS would not be significant. Alternatively,
if we assumed that CCRT was given to 30% of the patients
diagnosed in 1995–1998 and 100% of the patients diagnosed
in 1999–2002, the simulation showed that 2% of the time the
log-rank tests for OS would not be statistically significant (data
not shown).
DISCUSSION
The 1999 NCI alert was based on five randomized trials showing
improvement in OS with CCRT compared with radiation alone.
The Gynecologic Oncology Group (GOG) conducted a ran-
domized controlled trial, GOG 123, for patients with bulky FIGO
stage IB cervical cancers ≥4 cm in diameter (2). Patients were
randomized to radiotherapy alone or combination chemoradio-
therapy with weekly cisplatin. All patients had adjuvant extrafascial
hysterectomy. Compared to the RT alone group, the chemoradio-
therapy group had improved 4-year progression free survival (RR
0.51) and OS (RR 0.54).
The Radiation Therapy Oncology Group (RTOG) conducted
a randomized controlled trial, RTOG 90-01, comparing extended
field radiation therapy alone versus pelvic field chemoradiother-
apy for women with FIGO stage IIB–IVA cervical carcinoma (3).
Estimated 5-year OS and disease-free survival were both signifi-
cantly improved with chemoradiotherapy (73 and 67%) compared
to extended field radiation therapy alone (58 and 40%).
GOG 120 studied different chemoradiotherapy regimens in
FIGO IIB–IVA cervical cancer patients (4). All patients received
pelvic radiation therapy and intracavitary brachytherapy. Patients
were randomized to one of three arms of concurrent chemother-
apy: cisplatin alone versus cisplatin, fluorouracil and hydroxyurea
versus hydroxyurea alone. Both cisplatin containing regimens
were superior to hydroxyurea alone. Similarly, GOG 85 demon-
strated the superiority of CCRT with cisplatin and fluorouracil
over hydroxyurea alone for FIGO IIB–IVA cervical cancer patients
(5). These two studies supported cisplatin-based chemotherapy
for locoregional cervical cancer and added to the evidence for the
overall efficacy ofCCRT.
Finally, the Southwest Oncology Group (SWOG) 8797
trial demonstrated that adjuvant CCRT improved overall and
progression-free survival after radical hysterectomy and pelvic
lymphadenectomy in patients found to have positive margins,
positive parametria, or involved lymph nodes on pathology
(6). Cisplatin-based chemoradiotherapy increased the 4-year
progression-free survival to 80% compared to 63% for patients
receiving radiation alone. Similarly, chemoradiation increased
4-year OS to 81% compared to 71% for radiation alone.
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Table 2 | Survival of 1999–2002 compared to 1995–1998 stratified by age groups.
Age group Group size OS CSS
p-value by
log-rank
test
Hazard ratio
99-02 versus
95–98 (95% CI)
p-value by
log-rank
test
Hazard ratio
99-02 versus
95–98 (95% CI)
Proportion
of non-
CSDa (%)
<41 732 <0.01 0.68 (0.55, 0.83) <0.01 0.67 (0.54, 0.83) 7.2
41–55 1413 0.01 0.83 (0.72, 0.96) 0.02 0.83 (0.71, 0.97) 10.8
>55 1372 0.01 0.85 (0.75, 0.97) <0.01 0.81 (0.70, 0.94) 27.4
a“Non-CSD” is short for “Non-Cause Specific Death.” The “Non-CSD” patients were treated as censored in the cause specific survival (CSS) analysis.
Red color used to highlight statistically significant p-values.
Table 3 | Survival of 1999–2002 compared to 1995–1998 stratified by SEER registries.
SEER registry Size OS CSS
p-value by
log-rank
test
Hazard ratio
99-02 versus
95–98 (95% CI)
p-value by
log-rank
test
Hazard ratio
99-02 versus
95–98 (95% CI)
Proportion
of non-
CSDa (%)
San Francisco–Oakland SMSA 303 0.03 0.72 (0.53, 0.97) 0.05 0.71 (0.50, 1.00) 22.7
Connecticut 251 0.99 1.00 (0.73, 1.37) 0.33 0.84 (0.59, 1.20) 21.5
Metropolitan Detroit 374 <0.01 0.62 (0.48, 0.78) <0.01 0.54 (0.41, 0.72) 15.4
Hawaii 125 0.57 1.14 (0.72, 1.81) 0.89 1.03 (0.61, 1.78) 28
Iowa 253 0.31 0.85 (0.61, 1.17) 0.27 0.82 (0.58, 1.17) 13.9
New Mexico 166 0.89 1.03 (0.69, 1.53) 0.89 1.03 (0.67, 1.57) 11.2
Seattle (Puget Sound) 264 0.32 0.85 (0.62, 1.18) 0.46 0.88 (0.63, 1.24) 15.8
Utah 125 0.11 0.68 (0.43, 1.09) 0.08 0.63 (0.38, 1.06) 13.7
Metropolitan Atlanta 255 0.05 0.73 (0.53, 1.00) 0.03 0.69 (0.48, 0.97) 14.6
Alaska 7 0.81 0.75 (0.07, 8.42) 0.81 0.74 (0.07, 8.42) 0
San Jose–Monterey 177 0.06 0.68 (0.45, 1.02) 0.05 0.64 (0.41, 1.00) 16.3
Los Angeles 1194 0.10 0.88 (0.76, 1.02) 0.36 0.92 (0.78, 1.09) 18.8
Rural Georgia 23 <0.01 0.06 (0.01, 0.29) <0.01 0.10 (0.02, 0.50) 31.3
a“Non-_CSD” is short for “Non-Cause Specific Death”. The “Non-CSD” patients were treated as censored in the cause specific survival (CSS) analysis.
Red color used to highlight statistically significant p-values.
A recent meta-analysis including 13 trials that had uncon-
founded comparisons of chemoradiotherapy versus radiotherapy
alone concluded that there was a 6% improvement in 5-year OS
with chemoradiotherapy (HR= 0.81, p< 0.001) (9). Local and
distant recurrences were also reduced and disease-free survival
improved with chemoradiotherapy. The meta-analysis included
the GOG 123 and SWOG 8797 trials in the main analysis, and
it included the GOG 85, RTOG 90-01, and GOG 120 trials in
a sensitivity analysis that supported the findings of the main
analysis.
Our study similarly found an improvement in OS and CSS
for the years 1999–2002 (CCRT era) compared with years 1995–
1998 (RT era) in both unadjusted analyses (OS HR= 0.81, CSS
HR= 0.79) and adjusted analyses (multivariable OS HR= 0.78,
CSS HR= 0.76). Stratification by age group or geographic SEER
region did not significantly alter these results. These results pro-
vide indirect evidence that the increased usage of CCRT in the
era after the 1999 NCI alert may have improved OS and CSS for
patients with IB2-IVA cervical cancer.
From the multivariable analyses, we note that HRs for death
were significantly worse for age >55 versus ≤55, unmarried
status versus married, FIGO stages II–IVA versus IB2, non-
squamous histology versus squamous cell carcinoma, positive
lymph nodes versus negative lymph nodes, biopsy only/no
surgery versus local ablation/excision/hysterectomy/exenteration,
and other radiation type versus combined EBRT+ brachytherapy.
Similarly, HRs for cause-specific death were significantly worse
for FIGO stages II–IVA versus IB2, non-squamous histology
versus squamous cell carcinoma, positive lymph nodes versus
negative lymph nodes, biopsy only/no surgery versus local abla-
tion/excision/hysterectomy/exenteration, and other radiation type
versus combined EBRT+ brachytherapy. These results are consis-
tent with prior reports in the literature with respect to histology
(13, 14), clinical stage, and pelvic nodal status (15). The liter-
ature is mixed regarding age as a prognostic factor, with some
studies showing younger age as a poor prognostic factor and
others showing the opposite effect or no effect of age when
accounting for other variables (15–19). We found that age was
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Table 4 | Survival comparisons of 1999–2002 versus 1995–1998 when adjusted by variables individually using Cox Model (N = 3517).
Variable Size OS CSS
Estimate SE p-value Hazard ratio
(95% CI)
Estimate SE p-value Hazard ratio
(95% CI)
Race (ref = white) 2495
Non-white 1022 0.015 0.048 0.757 1.015 (0.924, 1.116) −0.032 0.054 0.551 0.968 (0.872, 1.076)
Year 1999–2002
(ref = 1995–1998)
−0.215 0.045 <0.001 0.807 (0.739, 0.881) −0.242 0.049 <0.001 0.785 (0.713, 0.864)
Marital status (ref = married) 2058
Unmarried 1459 0.225 0.045 <0.001 1.252 (1.146, 1.368) 0.139 0.049 0.005 1.150 (1.044, 1.266)
Year 1999–2002
(ref = 1995–1998)
−0.218 0.045 <0.001 0.804 (0.737, 0.877) −0.244 0.049 <0.001 0.783 (0.712, 0.862)
Figo stage (ref = IB2) 446
II 1732 0.359 0.082 <0.001 1.432 (1.219, 1.683) 0.373 0.093 <0.001 1.452 (1.210, 1.742)
III+ IVA 1339 1.147 0.081 <0.001 3.150 (2.684, 3.697) 1.210 0.091 <0.001 3.352 (2.800, 4.014)
Year 1999–2002
(ref = 1995–1998)
−0.234 0.045 <0.001 0.791 (0.725, 0.864) −0.262 0.049 <0.001 0.769 (0.699, 0.846)
Histology (ref = squamous
cell carcinoma)
2785
Adenocarcinoma 354 0.103 0.072 0.151 1.109 (0.963, 1.276) 0.164 0.077 0.035 1.178 (1.012, 1.371)
Other/unknown 378 0.238 0.069 0.0005 1.268 (1.109, 1.451) 0.294 0.074 <0.001 1.342 (1.160, 1.552)
Year 1999–2002
(ref = 1995–1998)
−0.216 0.045 <0.001 0.806 (0.739, 0.880) −0.244 0.049 <0.001 0.784 (0.713, 0.863)
Lymph node status
(ref = LN−)
1817
Distant LN+ 271 0.861 0.076 <0.001 2.366 (2.039, 2.747) 0.991 0.081 <0.001 2.696 (2.300, 3.160)
Regional LN+ 529 0.250 0.066 <0.001 1.284 (1.129, 1.460) 0.390 0.070 <0.001 1.477 (1.287, 1.696)
Other/unknown 900 0.520 0.052 <0.001 1.683 (1.520, 1.863) 0.543 0.058 <0.001 1.721 (1.536, 1.929)
Year 1999–2002
(ref = 1995–1998)
−0.196 0.045 <0.001 0.822 (0.753, 0.897) −0.226 0.049 <0.001 0.798 (0.725, 0.878)
Surgery extent (ref = no
surgery/incisional
biopsy/unknown)
2254
Local ablation or excision 248 −0.411 0.092 <0.001 0.663 (0.553, 0.794) −0.443 0.104 <0.001 0.642 (0.524, 0.788)
Hysterectomy/ exenteration/
other surgery
1015 −0.558 0.053 <0.001 0.572 (0.516, 0.634) −0.498 0.057 <0.001 0.607 (0.543, 0.679)
Year 1999–2002
(ref = 1995–1998)
−0.230 0.045 <0.001 0.794 (0.728, 0.867) −0.256 0.049 <0.001 0.774 (0.703, 0.852)
Radiation type
(ref = combined
EBRT+brachytherapy
2114
EBRT/brachytherapy/other 1403 0.351 0.044 <0.001 1.421 (1.303, 1.550) 0.376 0.049 <0.001 1.457 (1.324, 1.603)
Year 1999–2002
(ref = 1995–1998)
−0.225 0.045 <0.001 0.799 (0.732, 0.872) −0.252 0.049 <0.001 0.777 (0.706, 0.855)
Red color used to highlight statistically significant p-values.
not a significant factor for cervical cancer CSS on multivariable
analysis.
Our confidence in attributing the improved survival during
1999–2002 to CCRT depends on the assumption that the rates of
CCRT use were low between 1995 and 1998 and high between
1999 and 2002. While the primary analyses and outcomes are not
contingent on any specific assumptions of percentages of CCRT
use in the two time periods, the ability to attribute the outcomes
to CCRT is affected by these percentages. In the best case sce-
nario, where CCRT was given to 0% of the patients between
1995 and 1998 and 100% of the patients between 1999 and 2002,
one could confidently attribute the significant improvements in
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Table 5 | Best fitting Multivariable Cox model for overall survival (N = 3517, AIC = 31399).
Variable Size Parameter
estimate
SE p-value Hazard ratio (95% CI)
Year 1999–2002 [ref =1995–1998
(n=1758)]
1759 −0.250 0.045 <0.001 0.779 (0.713, 0.850)
Age [ref = <41 (n = 732)]
41–55 1413 −0.079 0.064 0.219 0.924 (0.815, 1.048)
>55 1372 0.221 0.063 <0.001 1.247 (1.102, 1.411)
Marital status [ref = married
(n = 2058)]
Unmarried 1459 0.100 0.046 0.029 1.106 (1.010, 1.210)
FIGO stage [ref = IB2 (n = 446)]
II 1732 0.207 0.086 0.015 1.230 (1.040, 1.455)
III+ IVA 1339 0.834 0.088 <0.001 2.301 (1.938, 2.734)
Histology [ref = squamous cell
carcinoma (n = 2785)]
Adenocarcinoma 354 0.234 0.072 0.001 1.263 (1.096, 1.456)
Other/unknown 378 0.308 0.069 <0.001 1.360 (1.187, 1.558)
Lymph node status [ref = LN−
(n = 1817)]
Distant LN+ 271 0.628 0.078 <0.001 1.874 (1.608, 2.184)
Regional LN+ 529 0.271 0.068 <0.001 1.311 (1.146, 1.499)
Other/unknown 900 0.282 0.053 <0.001 1.326 (1.194, 1.472)
Surgery Extent [ref = no
surgery/incisional
biopsy/unknown (n = 2254)]
Local ablation or excision 248 −0.311 0.093 <0.001 0.733 (0.611, 0.879)
Hysterectomy/exenteration/other
surgery
1015 −0.482 0.060 <0.001 0.618 (0.549, 0.694)
Radiation type [ref = combined
EBRT+brachytherapy (n = 2114)]
EBRT/brachytherapy/other 1403 0.409 0.046 <0.001 1.505 (1.375, 1.646)
Red color used to highlight statistically significant p-values.
survival in the latter time period to significant survival benefits
of CCRT use. A simulation was performed that showed robust-
ness of the overall study conclusions to moderate deviations (up
to 30% per time period) in the percentages of patients receiving
CCRT.
Data in support of our study assumptions and results come
from a population-based cohort study from Ontario, Canada,
which showed an increase in utilization of concurrent chemother-
apy from <10% of RT cases between 1992 and 1998 to over
60% of RT cases between 1999 and 2001 (20). Consistent with
this increased utilization of concurrent chemotherapy, the study
reported an increase in 3-year OS from 58.6% in the 1992–1998
cohort to 69.8% in the 1999–2001 cohort among patients treated
with primary RT (with or without chemotherapy).
One major limitation of using the SEER database for this
study was that chemotherapy usage was not recorded for analysis
in SEER*Stat. The SEER-Medicare linked database would con-
tain detailed information about chemotherapy utilization, but
approximately three-quarters of the women in our study were
under 65 years old and would not have Medicare data avail-
able. Additionally, for postoperative patients, the SEER data were
not sufficiently detailed to classify patients into cohorts that
would meet the Sedlis criteria for postoperative RT alone (21,
22) versus the Peters criteria for postoperative CCRT (6). Specif-
ically, data were not recorded in SEER*Stat for lymphovascular
invasion for cervical cancer, depth of cervical stromal invasion,
pathologic margin status for cervical cancer, and pathologic para-
metrial involvement. Inclusion of postoperative patients in the
overall analyses more likely biased the results in favor of the
null hypothesis because some of the patients in the 1999–2002
time period would have been appropriately treated with post-
operative RT alone, thereby diluting the impact of those treated
with CCRT.
A limitation of using the SEER database for the CSS analysis
was that causes of death other than cervical cancer were treated
as censored by the SEER database. This assumption could lead to
bias if the cervical cancer deaths and other deaths were not inde-
pendent. To account for this limitation, competing risk analyses
were performed that confirmed the significant difference in CSS
between the two time periods.
Other limitations include the retrospective nature of the study
and lack of data on performance status, comorbidities, and
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Table 6 | Best-fitting Multivariable Cox model for cause specific survival (N = 3517, AIC = 25951).
Variable Size Parameter
estimate
SE p-value Hazard ratio (95% CI)
Year 1999–2002 [ref = 1995–1998 (n=1758)] 1759 −0.274 0.049 <0.001 0.760 (0.690, 0.837)
FIGO stage [ref = IB2 (n = 446)]
II 1732 0.314 0.096 0.001 1.369 (1.135, 1.652)
III+ IVA 1339 0.995 0.097 <0.001 2.706 (2.236, 3.275)
Histology [ref = squamous cell carcinoma
(n = 2785)]
Adenocarcinoma 354 0.318 0.078 <0.001 1.374 (1.179, 1.601)
Other/unknown 378 0.352 0.075 <0.001 1.422 (1.227, 1.647)
Lymph node status [ref = LN− (n = 1817)]
Distant LN+ 271 0.730 0.083 <0.001 2.075 (1.763, 2.444)
Regional LN+ 529 0.384 0.073 <0.001 1.468 (1.272, 1.694)
Other/unknown 900 0.314 0.060 <0.001 1.369 (1.218, 1.538)
Surgery Extent [ref = no surgery/incisional
biopsy/unknown (n = 2254)]
Local Ablation or excision 248 −0.365 0.104 0.0005 0.694 (0.565, 0.852)
Hysterectomy/exenteration/other surgery 1015 −0.465 0.064 <0.001 0.628 (0.553, 0.714)
Radiation type [ref = combined
EBRT+brachytherapy (n = 2114)]
EBRT/brachytherapy/other 1403 0.422 0.050 <0.001 1.525 (1.382, 1.684)
Red color used to highlight statistically significant p-values.
other factors that may affect the decision to give concurrent
chemotherapy. There may be unidentified differences in patient
characteristics or non-chemotherapy treatments between the two
time periods that could contribute to the observed survival differ-
ences. On the other hand, the study is strengthened by the large size
of the study cohort and the narrow time periods studied (thereby
diminishing the effects of stage migration or changes to radiation
or surgical techniques).
In this study, we have not addressed the higher toxicity rates
associated with CCRT since the SEER database does not include
this information. Additional research is needed to discover new
combinations of radiotherapy and systemic agents that can reduce
toxicities and complications without compromising the survival
benefits of CCRT.
In conclusion, since no other known changes in the demo-
graphics or management of locoregional cervical cancer occurred
during the study time period, this study offers indirect evidence
that the adoption of CCRT after the 1999 NCI alert improved
both OS and CSS in patients with IB2-IVA cervical cancer. Fur-
thermore, it appears that the recommendation to add concurrent
chemotherapy to RT was adopted in a rapid time frame at least
comparable to the adoption of clinical trial recommendations
in other disease settings (23–25). To our knowledge, this is the
first population-level study in the United States demonstrating
improved survival for cervical cancer patients treated in the era of
concurrent chemoradiation therapy.
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